Identification of the Peptide Binding Motif for HLA-B44, One of the Most Common HLA-B Alleles in the Caucasian Population
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Most peptides that bind to a particular MHC class I molecule share amino acid residues that are thought to physically "anchor" the peptide to polymorphic pockets within the class I binding site. Sequence analysis of endogenous peptides bound to HLA-B44 revealed two potential dominant anchor residues: Glu at P2 and Tyr, or occasionally Phe, at P9. In vitro assembly assays employing synthetic peptides and recombinant HLA-B44 produced by Escherichia coli revealed that an acidic amino acid at P2 was necessary for promoting stable peptide binding to HLA-B44. Surprisingly, although Tyr was almost exclusively found at P9 of the endogenous peptide sequences, a wide variety of amino acid residues such as Leu, Ala, Arg, Lys, His, and Phe could be tolerated at this position. Using this information, we identified antigenic peptides from the influenza virus components nonstructural protein 1 and nucleoprotein that are presented by HLA-B44 to antiinfluenza type A cytotoxic T lymphocytes. In addition, cytotoxic T lymphocytes induced by these antigenic peptides were shown to be capable of recognizing endogenously processed peptides from influenza-infected cells, indicating a potential use for these peptides in vaccine development. Finally, molecular models were created to investigate the possible ways in which the anchor residues might function to stabilize the binding of peptides to HLA-B44, and these models indicate that the acidic residue at P2 most likely interacts primarily with Lys 45 of the HLA-B44 heavy chain and makes additional contacts with Ser 67 and Tyr 9.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most members of the B44 supertype share a preference for peptides with Glu (E) at anchor position P2 and polar and hydrophobic residues at the C terminus (Fig. 2J) (54, 56).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [56]
Citations
Cites
A comprehensive set of sequence analysis programs for the VAX
Devereux, J., Haeberli, P., & Smithies, O. (1984) · Nucleic Acids Research · doi:10.1093/nar/12.1part1.387 · Cited by 14,222
Antibodies, a laboratory manual
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90130-3 · Cited by 12,366
Structure of the human class I histocompatibility antigen, HLA-A2
Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger, J. L., & Wiley, D. C. (1987) · Nature · doi:10.1038/329506a0 · Cited by 3,472
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
Falk, K., Rötzschke, O., Stevanovié, S., Jung, G., & Rammensee, H.-G. (1991) · Nature · doi:10.1038/351290a0 · Cited by 2,411
Townsend, A. (1986) · Cell · doi:10.1016/0092-8674(86)90019-x · Cited by 1,699
Antigen Recognition by Class I-Restricted T Lymphocytes
Townsend, A., & Bodmer, H. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.003125 · Cited by 1,198
Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution
Saper, M. A., Bjorkman, P. J., & Wiley, D. C. (1991) · Journal of Molecular Biology · doi:10.1016/0022-2836(91)90567-p · Cited by 1,077
Crystal Structures of Two Viral Peptides in Complex with Murine MHC Class I H-2K b
Fremont, D. H., Matsumura, M., Stura, E. A., Peterson, P. A., & Wilson, L. A. (1992) · Science · doi:10.1126/science.1323877 · Cited by 861
Identification of self peptides bound to purified HLA-B27
Jardetzky, T. S., Lane, W. S., Robinson, R. A., Madden, D. R., & Wiley, D. C. (1991) · Nature · doi:10.1038/353326a0 · Cited by 827
Peptides Naturally Presented by MHC Class I Molecules
Rammensee, H. G., Falk, K., & Rötzschke, O. (1993) · Annual Review of Immunology · doi:10.1146/annurev.iy.11.040193.001241 · Cited by 799
Cited by
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism
Sette, A., & Sidney, J. (1999) · Immunogenetics · doi:10.1007/s002510050594 · Cited by 635
“DiBrino et al. 1995; 20.”
BackgroundInfluentialLee, L. Y.-H., Ha, D. L. A., Simmons, C., de Jong, M. D., Chau, N. V. V., Schumacher, R., Peng, Y. C., McMichael, A. J., Farrar, J. J., Smith, G. L., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32460 · Cited by 422
Optimization of the MHC Class I Peptide Cargo Is Dependent on Tapasin
Williams, A. P., Peh, C. A., Purcell, A. W., McCluskey, J., & Elliott, T. (2002) · Immunity · doi:10.1016/s1074-7613(02)00304-7 · Cited by 353
Stability-mediated epistasis constrains the evolution of an influenza protein
Gong, L. I., Suchard, M. A., & Bloom, J. D. (2013) · eLife · doi:10.7554/elife.00631 · Cited by 336
“All three destabilizing mutations occur in characterized epitopes (DiBrino et al., 1995; Voeten et al., 2000; Rimmelzwaan et al., 2004b; Berkhoff et al., 2007; Assarsson et al., 2008; Alexander et al., 2010; Cheung et al., 2012), and mutations at two of these sites have been shown to reduce CTL…”
BackgroundPeh, C. A., Burrows, S. R., Barnden, M., Khanna, R., Cresswell, P., Moss, D. J., & McCluskey, J. (1998) · Immunity · doi:10.1016/s1074-7613(00)80558-0 · Cited by 252
HLA supertypes and supermotifs: a functional perspective on HLA polymorphism
Sette, A., & Sidney, J. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80124-6 · Cited by 243
Disulfide Bond Isomerization and the Assembly of MHC Class I-Peptide Complexes
Dick, T. P., Bangia, N., Peaper, D. R., & Cresswell, P. (2002) · Immunity · doi:10.1016/s1074-7613(02)00263-7 · Cited by 229
A Human Minor Histocompatibility Antigen Specific for B Cell Acute Lymphoblastic Leukemia
Dolstra, H., Fredrix, H., Maas, F., Coulie, P. G., Brasseur, F., Mensink, E., Adema, G. J., de Witte, T. M., Figdor, C. G., & van de Wiel-van Kemenade, E. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.301 · Cited by 223
“The consensus peptide binding motif for HLA-B44 shows a predominance for Glu at position 2, and Tyr or Phe at position 9 or 10 (18, 19).”
Macdonald, W. A., Purcell, A. W., Mifsud, N. A., Ely, L. K., Williams, D. S., Chang, L., Gorman, J. J., Clements, C. S., Kjer-Nielsen, L., Koelle, D. M., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030066 · Cited by 204
“Apart from the previously reported P2Glu and P Tyr/Phe anchor residues (12, 18, 19), minor differences were noted between subdominant anchor residues with more pronounced yields of valine at P3 for B*4403 and tryptophan at P9 for B*4402 (Fig.”
BackgroundResultInfluentialPantaleo, G., Soudeyns, H., Demarest, J. F., Vaccarezza, M., Graziosi, C., Paolucci, S., Daucher, M., Cohen, O. J., Denis, F., Biddison, W. E., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9848 · Cited by 201
Self-citationImmuno‐informatics: Mining genomes for vaccine components
De Groot, A. S., Sbai, H., Aubin, C. S., McMurry, J., & Martin, W. (2002) · Immunology & Cell Biology · doi:10.1046/j.1440-1711.2002.01092.x · Cited by 179
“Peptides presented by class II molecules are longer and more variable in size than those presented by class I molecules, and usually contain three main anchor residues located at the relative positions 1, 6 and 9”
BackgroundPark, B., Kim, Y., Shin, J., Lee, S., Cho, K., Früh, K., Lee, S. W., & Ahn, K. (2004) · Immunity · doi:10.1016/s1074-7613(03)00355-8 · Cited by 152
Mathew, A., Kurane, I., Rothman, A. L., Zeng, L., Brinton, M. A., & Ennis, F. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118964 · Cited by 124
“Using the HLA-B44 motif, three different antigenic peptides from both influenza NS1 and NP proteins were shown to be presented by HLA-B44 to antiinfluenza type A–specific CTLs from one donor (24).”
Natural Selection on the Influenza Virus Genome
Suzuki, Y. (2006) · Molecular Biology and Evolution · doi:10.1093/molbev/msl050 · Cited by 121
Nucleoprotein of influenza A virus is a major target of immunodominant CD8+ T‐cell responses
Grant, E. J., Wu, C., Chan, K., Eckle, S. B. G., Bharadwaj, M., Zou, Q. M., Kedzierska, K., & Chen, W. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2012.78 · Cited by 114
van de Sandt, C. E., Kreijtz, J. H. C. M., de Mutsert, G., Geelhoed-Mieras, M. M., Hillaire, M. L. B., Trierum, S. E. V.-V., Osterhaus, A. D. M. E., Fouchier, R. A. M., & Rimmelzwaan, G. F. (2013) · Journal of Virology · doi:10.1128/jvi.02843-13 · Cited by 116
Optimizing vaccine design for cellular processing, MHC binding and TCR recognition
Sette, A., Newman, M. J., Livingston, B. D., McKinney, D. M., Sidney, J., Ishioka, G. Y., Tangri, S., Alexander, J., Fikes, J. D., & Chesnut, R. W. (2002) · Tissue Antigens · doi:10.1034/j.1399-0039.2002.590601.x · Cited by 107
Archbold, J. K., Macdonald, W. A., Gras, S., Ely, L. K., Miles, J. J., Bell, M. J., Brennan, R. M., Beddoe, T., Wilce, M. C. J., Clements, C. S., et al. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20082136 · Cited by 113
Functional Constraints of Influenza A Virus Epitopes Limit Escape from Cytotoxic T Lymphocytes
Berkhoff, E. G. M., de Wit, E., Geelhoed-Mieras, M. M., Boon, A. C. M., Symons, J., Fouchier, R. A. M., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2005) · Journal of Virology · doi:10.1128/jvi.79.17.11239-11246.2005 · Cited by 105
The human leukocyte antigen-presented ligandome of B lymphocytes
Hassan, C., Kester, M. G. D., de Ru, A. H., Hombrink, P., Drijfhout, J. W., Nijveen, H., Leunissen, J. A. M., Heemskerk, M. H. M., Falkenburg, J. H. F., & van Veelen, P. A. (2013) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m112.024810 · Cited by 98
The evolution of human influenza A viruses from 1999 to 2006: A complete genome study
Bragstad, K., Nielsen, L. P., & Fomsgaard, A. (2008) · Virology Journal · doi:10.1186/1743-422x-5-40 · Cited by 118
“There has been a substitution, F166L, in the HLA-B*44 NS1 158–166 CTL epitope [24] for 2000–2001 H1N1 isolates in both lineage I and lineage II.”
BackgroundHerman, J., van der Bruggen, P., Luescher, I. F., Mandruzzato, S., Romero, P. J., Thonnard, J., Fleischhauer, K., Boon, T., & Coulie, P. G. (1996) · Immunogenetics · doi:10.1007/bf02199806 · Cited by 104
“…peptides recognized by T lymphocytes on HLAB44, or eluted from HLA-B44 molecules, often contain Glu in position 2 and Tyr or Phe in position 9 or 10 (Brichard et al. 1995; Buseyne et al. 1993; Coulie et al. 1995; DiBrino et al. 1995; Fleischhauer et al. 1994; Khanna et al. 1992; Kita et al. 1993).”
BackgroundPark, B., Lee, S., Kim, E., & Ahn, K. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.2.961 · Cited by 94
“We incubated intact microsomes derived from B4402 and B44D114H transfectants with or without tapasin and AEIDKVTGY peptide, a high-affinity ligand for B4402 (19), in the presence of the competitors at different concentrations.”
MethodGras, S., Burrows, S. R., Turner, S. J., Sewell, A. K., McCluskey, J., & Rossjohn, J. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01159.x · Cited by 98
Broad CD8+ T cell cross-recognition of distinct influenza A strains in humans
Grant, E. J., Josephs, T. M., Loh, L., Clemens, E. B., Sant, S. A., Bharadwaj, M., Chen, W., Rossjohn, J., Gras, S., & Kedzierska, K. (2018) · Nature Communications · doi:10.1038/s41467-018-07815-5 · Cited by 84
Fitness costs limit escape from cytotoxic T lymphocytes by influenza A viruses
Berkhoff, E. G. M., de Wit, E., Geelhoed-Mieras, M. M., Boon, A. C. M., Symons, J., Fouchier, R. A. M., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.051 · Cited by 68
Epistatically Interacting Substitutions Are Enriched during Adaptive Protein Evolution
Gong, L. I., & Bloom, J. D. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004328 · Cited by 72
“Numerous experimental studies have identified epitopes in NP that are targeted by human CTLs (see for example [30,53–57] plus many others).”
BackgroundRohrlich, P. (2003) · International Immunology · doi:10.1093/intimm/dxg073 · Cited by 60
Berkhoff, E. G. M., Geelhoed-Mieras, M. M., Fouchier, R. A. M., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2007) · Journal of General Virology · doi:10.1099/vir.0.82120-0 · Cited by 52
“…the use of prototypic strains in these studies may have resulted in a bias towards the preferential identification of conserved CTL epitopes (DiBrino et al., 1993, 1994, 1995; Gianfrani et al., 2000; Jameson et al., 1999; Macken et al., 2001; Man et al., 1995; Rohrlich et al., 2003;…”
BackgroundSimultaneous Prediction of Binding Capacity for Multiple Molecules of the HLA B44 Supertype
Sidney, J., Southwood, S., Pasquetto, V., & Sette, A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.5964 · Cited by 49
Mechanistic Basis for Epitope Proofreading in the Peptide-Loading Complex
Fleischmann, G., Fisette, O., Thomas, C., Wieneke, R., Tumulka, F., Schneeweiß, C., Springer, S., Schäfer, L. V., & Tampé, R. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501515 · Cited by 47
“The equilibrium dissociation constants determined by fluorescence anisotropy are in agreement with previously reported data (48).”
ResultCummings, A. L., Gukasyan, J., Lu, H. Y., Grogan, T., Sunga, G. M., Fares, C. M., Hornstein, N. J., Zaretsky, J. M., Carroll, J., Bachrach, B., et al. (2020) · Nature Cancer · doi:10.1038/s43018-020-00140-1 · Cited by 47
Boucherma, R., Kridane‐Miledi, H., Bouziat, R., Rasmussen, M., Gatard-Scheikl, T., Vives, F. L., Lemercier, B., Lim, A., Berard, M., BenMohamed, L., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300483 · Cited by 44
“VSDGGPNLY A*01 Influenza A basic polymerase I 591–599 (46) 201/134/71/59 EADPTGHSY A*01 MAGE-1 161–169 (47) 287/212/123/27 RYLKDQQLL A*24 HIV I gp41 583–591 (48), 330/162/74/62/56 TYQIYQEPF A*24 HIV I polymerase 493–501 (49) 83/44/45/35/12 DSRLAFHHM A*24 HIV nef 186–194 (50) 0/0/0/0 RAKFKQLL B*08 EBV lytic cycle Ag BZ…”
Immunodominance Hierarchies and Gender Bias in Direct TCD8-Cell Alloreactivity
Mifsud, N. A., Purcell, A. W., Chen, W., Holdsworth, R. F., Tait, B. D., & McCluskey, J. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.02044.x · Cited by 39
Thammavongsa, V., Raghuraman, G., Filzen, T. M., Collins, K. L., & Raghavan, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.5.3150 · Cited by 37
“Two HLA-B*44-specific peptides, SEIDTVAKY (41) and EEFGRAFSF (42) were synthesized, and additionally, two nonapeptide libraries were synthesized, one of which was completely random at each position while the other was synthesized with a HLA-B*44 glutamic acid anchor at position 2.”
MethodHerman, J., Jongeneel, V. C., Kuznetsov, D. A., & Coulie, P. G. (1999) · Tissue Antigens · doi:10.1034/j.1399-0039.1999.530201.x · Cited by 37
Macdonald, W. A., Williams, D. S., Clements, C. S., Gorman, J. J., Kjer‐Nielsen, L., Brööks, A. G., McCluskey, J., Rossjohn, J., & Purcell, A. W. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03149-6 · Cited by 37
Nef-Specific CD8+ T Cell Responses Contribute to HIV-1 Immune Control
Adland, E., Carlson, J. M., Paioni, P., Kløverpris, H. N., Shapiro, R., Ogwu, A., Riddell, L., Luzzi, G. A., Chen, F., Balachandran, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073117 · Cited by 41
Romero‐Gómez, M., González‐Escribano, M. F., Torres, B., Barroso, N., Montes‐Cano, M. A., Sánchez-Muñoz, D., Núñez‐Roldán, A., & Aguilar‐Reina, J. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00366-6 · Cited by 34
Proteomics in Vaccinology and Immunobiology:An Informatics Perspective of the Immunone
Doytchinova, I. A., Taylor, P. D., & Flower, D. R. (2003) · BioMed Research International · doi:10.1155/s1110724303209232 · Cited by 35
“It is founded on a series of important observations about peptide binding to MHC molecules [95, 96, 97, 98, 99, 100, 101, 102] and has been used in a number of applications [103, 104].”
BackgroundEly, L. K., Green, K. J., Beddoe, T., Clements, C. S., Miles, J. J., Bottomley, S., Zernich, D., Kjer‐Nielsen, L., Purcell, A. W., McCluskey, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.9.5593 · Cited by 33
Purcell, A. W., & Gorman, J. J. (2001) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00361-6 · Cited by 35
T-Cell Immunity to Influenza A Viruses
Grant, E. J., Chen, L., Quiñones‐Parra, S. M., Pang, K. C., Kedzierska, K., & Chen, W. (2013) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2013010019 · Cited by 36
Hala, M., Hartmann, B. L., Böck, G., Geley, S., & Kofler, R. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19961127)68:5<663::aid-ijc17>3.0.co;2-2 · Cited by 66
Baxter‐Lowe, L. A., Maiers, M. J., Spellman, S. R., Haagenson, M. D., Wang, T., Fernández-Viña, M., Marsh, S. G. E., Horowitz, M. M., & Hurley, C. K. (2009) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.04.015 · Cited by 26
Luescher, I. F., Romero, P. J., Kuznetsov, D. A., Rimoldi, D., Coulie, P. G., Cerottini, J., & Jongeneel, C. V. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.21.12463 · Cited by 25
Paris, R., Bejrachandra, S., Karnasuta, C., Chandanayingyong, D., Kunachiwa, W., Leetrakool, N., Prakalapakorn, S. G., D, P. T. M., Nitayaphan, S., Pitisuttithum, P., et al. (2004) · Tissue Antigens · doi:10.1111/j.1399-0039.2004.00270.x · Cited by 20
Morgan, S. M., Wilkinson, G. W. G., Floettmann, E., Blake, N. W., & Rickinson, A. B. (1996) · Journal of Virology · doi:10.1128/jvi.70.4.2394-2402.1996 · Cited by 20
“Interestingly, this sequence does not contain either a glutamate at position 2 or a tyrosine at position9or10,bothrecentlyidentifiedascommonfeaturesof HLA-B44.03-binding peptides ( 8 ).”
BackgroundYu, C., Fang, X., Tian, S., & Liu, H. (2025) · Nature Machine Intelligence · doi:10.1038/s42256-024-00973-w · Cited by 23
“Similarly, other studies have described preferential amino acids for HLA-B8, HLA-B14, HLA-B27, and HLA-B44, all of which were well-represented in our attention heatmaps [53–56].”
The HLA-A*6601 peptide motif: prediction by pocket structure and verification by peptide analysis
Seeger, F. H., Schirle, M., Gatfield, J., Arnold, D., Keilholz, W., Nickolaus, P., Rammensee, H., & Stevanović, S. (1999) · Immunogenetics · doi:10.1007/s002510050539 · Cited by 17
“The prediction was correct in postulating E in P2 of HLA-B44 ligands, but incorrect regarding P9 : instead of the postulated basic and hydrophobic residues, in the meantime only aromatic residues have emerged as the dominant P9 anchor (Fleischhauer et al. 1994; DiBrino et al. 1995 ).”
BackgroundSu, C. T.-T., Schönbach, C., & Kwoh, C. K. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-s2-s21 · Cited by 16
“Eleven epitopes (50, 128, 251, 412, 463, 493, 514, 131, 229, 400, and 259) bound in similar orientations to HLA-B*4405 with Glu at position 2 and residues at the C-terminus binding to the B and F pockets of the HLAB*4405, respectively [13-15].”
Association study between HLA-A, -B, -C, -DRB1 alleles and Psoriatic arthritis in southern France
Massy, E., Pedini, P., Pollet, E., Martin, M., Roudier, J., Picard, C., & Balandraud, N. (2022) · Human Immunology · doi:10.1016/j.humimm.2022.04.001 · Cited by 9
Herman, J., van der Bruggen, P., Luescher, I. F., Mandruzzato, S., Romero, P. J., Thonnard, J., Fleischhauer, K., Boon, T., & Coulie, P. G. (1996) · Immunogenetics · doi:10.1007/s002510050078 · Cited by 9
Stroobant, V., Demotte, N., Luiten, R. M., Leonhardt, R. M., Cresswell, P., Bonehill, A., Michaux, A., Ma, W., Mulder, A., den Eynde, B. J. V., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201141954 · Cited by 8
Evidence of focusing the MHC class I immunopeptidome by tapasin
Darley, R., Illing, P. T., Duriez, P. J., Bailey, A. G., Purcell, A. W., van Hateren, A., & Elliott, T. J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1563789 · Cited by 8
Immunogenetics Of Drug-Induced Skin Blistering Disorders. Part Ii: Synthesis
Bowman, C., & Delrieu, O. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.23 · Cited by 7
Autoimmune alleles at the major histocompatibility locus modify melanoma susceptibility
Talwar, J. V., Laub, D., Pagadala, M. S., Castro, A., Lewis, M., Luebeck, E. G., Gorman, B. R., Pan, C., Dong, F. N., Markianos, K., et al. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.05.013 · Cited by 5
Kaur, A., Surnilla, A., Zaitouna, A. J., Basrur, V., Mumphrey, M. B., Grigorova, I., Cieslik, M. P., Carrington, M. N., Nesvizhskii, A. I., & Raghavan, M. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2300232 · Cited by 5
Rammensee, H., Bachmann, J., & Stevanović, S. (1997) · Molecular biology intelligence unit · doi:10.1007/978-3-662-22162-4_4 · Cited by 5
Nkenfou, C. N. (2015) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.1000439 · Cited by 3
“Although Tyr is almost exclusively found at P9, a wide variety of amino acid residues such as Leu, Ala, Arg, Lys, His and Phe could be tolerated at this position [40].”
BackgroundComputational investigation of peptide binding stabilities of HLA-B*27 and HLA-B*44 alleles
Bunsuz, A., Serçinoğlu, O., & Özbek, P. (2019) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2019.107195 · Cited by 3
Rammensee, H., Bachmann, J., & Stevanović, S. (1997) · Molecular biology intelligence unit · doi:10.1007/978-3-662-22162-4_5 · Cited by 2
Peptides as Targets of T Cell-Mediated Immune Responses
Martinꝉ, R. (2006) · Elsevier eBooks · doi:10.1016/b978-012369442-3/50087-8 · Cited by 1
Mathew, A. (1999) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/5gyk-5e91
A unique murine monoclonal antibody recognizing HLA-B53, B37, B51, B52, +/−B44
Etessami, S., Tarsitani, C., Lias, M., Broadous, M., Conger, N., Randall, G., Delory, M., Bahrami, S., & Lee, J.-H. (2001) · Human Immunology · doi:10.1016/s0198-8859(01)00254-3
Evasion of influenza A viruses from human T-cell immunity
Berkhoff, E. G. M. (2007) · EUR Research Repository (Erasmus University Rotterdam)
Computational discovery of vaccine targets
Zhang, G. (2008) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/14139
“The binding motif method has been widely applied for MHC binding peptide prediction [90-92].”
MethodSu, T. T. C. (2014) · DR-NTU (Nanyang Technological University) · doi:10.32657/10356/62097
Sant, A. J. (2003) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.1015306.196306
Zhang, Z., Wu, W., Wei, L., Qi, H., & Wang, X. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.07.579420
Metadata
- Authors
- DiBrino, M., Parker, K. C., Margulies, D. H., Shiloach, J., Turner, R. V., Biddison, W. E., & Coligan, J. E.
- Affiliations
- National Institutes of Health (US)
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1995-08-15
- Volume
- 34
- Issue
- 32
- Pages
- 10130-10138
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2009271567
- Cited by
- 71
- References
- 42
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 2 · 2022: 1 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 2 · 2014: 2 · 2013: 8 · 2012: 2
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- HLA-B44, peptide binding motifs, anchor residues, antigenic peptides, influenza virus, NS1 protein, nucleocapsid protein, cytotoxic T lymphocytes, vaccine development, molecular modeling
- MeSH terms
- Alleles, Amino Acid Sequence, Epitopes, Base Sequence, Binding Sites, Capsid, Humans, Models, Molecular, Molecular Sequence Data, Influenza A virus, Peptides, T-Lymphocytes, HLA-B Antigens, Viral Nonstructural Proteins, DNA Primers, White People, HLA-B44 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.